Gedatolisib moves frontline in HR+/HER2– metastatic breast cancer, adding endocrine-sensitive patients and testing triplets vs ribociclib to boost PFS.
Dr Danny Nguyen discusses the shift of clinical trials to community settings, the impact of AI in oncology, and the latest drug approvals in lung cancer care.
Cancer breakthroughs surge, but trials and novel therapies stay out of reach for many. See how community care, policy, and design can close gaps.
Global phase 3 trial tests safusidenib maintenance after chemoradiotherapy, aiming to delay recurrence and improve survival in IDH1-mutant astrocytoma.
Panelists discuss how emerging targeted agents are poised to reshape the therapeutic landscape for EGFR-mutant NSCLC in the coming years.
Panelists discuss how proactive sequencing strategies optimize long-term outcomes in EGFR-mutant non–small-cell lung cancer (NSCLC) by anticipating resistance patterns.
Panelists discuss how patient-centered counseling and shared decision-making shape personalized treatment journeys in EGFR-mutant non–small-cell lung cancer (NSCLC).
Panelists discuss how adherence to guidelines and vigilant imaging support optimal management of CNS disease in EGFR-mutant non–small-cell lung cancer.
Panelists discuss how real-world practice blends evidence-based guidance with individualized adjustments for high-risk EGFR-mutant non–small-cell lung cancer (NSCLC) cases.
Panelists discuss how trial data and practical considerations inform the nuanced choice between amivantamab–lazertinib and osimertinib in managing EGFR-mutant non–small-cell lung cancer (NSCLC) with CNS disease.
Panelists discuss how personalized molecular insights drive first-line therapy choices in EGFR-mutant NSCLC with complex metastatic profiles.
FDA's new guidance clarifies overall survival data collection in clinical trials, emphasizing long-term follow-up, subgroup analysis, and trial design considerations.
Dr Harpreet Singh explores the FDA's new guidance on overall survival as a clinical trial endpoint, addressing its implications and challenges in oncology.
A groundbreaking trial for TYRA-300, an oral FGFR3 inhibitor, aims to transform treatment for patients with low-grade intermediate-risk bladder cancer.
Travel barriers and lack of local sites hinder clinical trial enrollment for underserved patients, and decentralizing trials is key to improving access, according to Mariam Eskander, MD, MPH.
A groundbreaking telehealth trial offers remote access to innovative pancreatic cancer treatment, enhancing patient participation and care coordination nationwide.
The pivotal AMPLIFY trial aims to support FDA approval of ⁶⁴Cu-SAR-bisPSMA as a best-in-class imaging tool in prostate cancer.
Cohort 1 of the GTB-3650 phase 1 trial completed with no safety issues observed in patients with CD33-expressing hematologic malignancies.
Deepak Bhamidipati, MD, discusses a review conducted to investigate how the design of early-phase clinical trials has evolved.
Deepak Bhamidipati, MD, discusses the impact of the FDA's Project Optimus on early-phase drug development protocols.
Manmeet Ahluwalia, MD, MBA, FASCO, highlights genomic testing as a crucial area of current research with immediate implications for patients with brain cancer.
A phase 1 trial of mRNA-4106 has dosed its first patient with an advanced or metastatic solid tumor.
Mack Roach III, MD, discusses concerns about how tariffs and restrictions on international collaboration could negatively affect cancer research and treatment.
Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.
Levee Medical has begun its pivotal ARID II trial, studying the Voro Scaffold for improved continence after prostatectomy.
Following promising phase 1 data, TCMCB07 is being further evaluated in a phase 2 trial for the treatment of patients with stage IV colorectal cancer.
A phase 1/2 trial of CRISPR-engineered eTIL therapy KSQ-004EX for advanced solid tumors has dosed its first patient.
A phase 1 open-label trial is underway, evaluating the safety and efficacy of CT-95 in patients with mesothelin-expressing advanced solid tumors.
The fourth cohort of an ongoing phase 1/2 has dosed its first patient with TTX-MC138 in advanced solid tumors.